Cargando…

The Effects of Oral Magnesium Supplementation on Glycemic Response among Type 2 Diabetes Patients

Background: Magnesium (Mg) supplementation may help control glycemic response among type 2 diabetes (T2D) patients. Objective: This study means to determine whether Mg supplementation improves glycemic control indicators in patients with T2D. Methods: After one week of the dietary stabilization phas...

Descripción completa

Detalles Bibliográficos
Autores principales: ELDerawi, Wafaa A., Naser, Ihab A., Taleb, Mahmmoud H., Abutair, Ayman S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356710/
https://www.ncbi.nlm.nih.gov/pubmed/30587761
http://dx.doi.org/10.3390/nu11010044
_version_ 1783391615569625088
author ELDerawi, Wafaa A.
Naser, Ihab A.
Taleb, Mahmmoud H.
Abutair, Ayman S.
author_facet ELDerawi, Wafaa A.
Naser, Ihab A.
Taleb, Mahmmoud H.
Abutair, Ayman S.
author_sort ELDerawi, Wafaa A.
collection PubMed
description Background: Magnesium (Mg) supplementation may help control glycemic response among type 2 diabetes (T2D) patients. Objective: This study means to determine whether Mg supplementation improves glycemic control indicators in patients with T2D. Methods: After one week of the dietary stabilization phase, 42 T2D patients were stratified according to sex, age, fasting blood sugar (FBS) and Mg levels and then randomly allocated into two groups. The intervention group was on 250 mg/day of elemental Mg for three months while the control group did not receive any type of supplements throughout the intervention period. Results: The daily administration of 250 mg of elemental Mg indicated a significant improvement in HbA1C (8.32 to 7.96%, p < 0.001), insulin levels (IL) (15.56 to 12.18 μIU/mL, p < 0.001), C-peptide (2.28 to 1.90 ng/mL, p = 0.001), HOMA.IR (6.16 to 4.44, p < 0.001) and HOMA.β% (59.99 to 52.37, p = 0.036) of the intervention group when compared with the control group after three months of intervention. Conclusion: The results of this study revealed that oral Mg supplementation reduces insulin resistance and improves the glycemic control indicators among T2D patients. Trial registration: current controlled trials PHRC/HC/32/15. Registered 5 October 2015.
format Online
Article
Text
id pubmed-6356710
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63567102019-02-01 The Effects of Oral Magnesium Supplementation on Glycemic Response among Type 2 Diabetes Patients ELDerawi, Wafaa A. Naser, Ihab A. Taleb, Mahmmoud H. Abutair, Ayman S. Nutrients Article Background: Magnesium (Mg) supplementation may help control glycemic response among type 2 diabetes (T2D) patients. Objective: This study means to determine whether Mg supplementation improves glycemic control indicators in patients with T2D. Methods: After one week of the dietary stabilization phase, 42 T2D patients were stratified according to sex, age, fasting blood sugar (FBS) and Mg levels and then randomly allocated into two groups. The intervention group was on 250 mg/day of elemental Mg for three months while the control group did not receive any type of supplements throughout the intervention period. Results: The daily administration of 250 mg of elemental Mg indicated a significant improvement in HbA1C (8.32 to 7.96%, p < 0.001), insulin levels (IL) (15.56 to 12.18 μIU/mL, p < 0.001), C-peptide (2.28 to 1.90 ng/mL, p = 0.001), HOMA.IR (6.16 to 4.44, p < 0.001) and HOMA.β% (59.99 to 52.37, p = 0.036) of the intervention group when compared with the control group after three months of intervention. Conclusion: The results of this study revealed that oral Mg supplementation reduces insulin resistance and improves the glycemic control indicators among T2D patients. Trial registration: current controlled trials PHRC/HC/32/15. Registered 5 October 2015. MDPI 2018-12-26 /pmc/articles/PMC6356710/ /pubmed/30587761 http://dx.doi.org/10.3390/nu11010044 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
ELDerawi, Wafaa A.
Naser, Ihab A.
Taleb, Mahmmoud H.
Abutair, Ayman S.
The Effects of Oral Magnesium Supplementation on Glycemic Response among Type 2 Diabetes Patients
title The Effects of Oral Magnesium Supplementation on Glycemic Response among Type 2 Diabetes Patients
title_full The Effects of Oral Magnesium Supplementation on Glycemic Response among Type 2 Diabetes Patients
title_fullStr The Effects of Oral Magnesium Supplementation on Glycemic Response among Type 2 Diabetes Patients
title_full_unstemmed The Effects of Oral Magnesium Supplementation on Glycemic Response among Type 2 Diabetes Patients
title_short The Effects of Oral Magnesium Supplementation on Glycemic Response among Type 2 Diabetes Patients
title_sort effects of oral magnesium supplementation on glycemic response among type 2 diabetes patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356710/
https://www.ncbi.nlm.nih.gov/pubmed/30587761
http://dx.doi.org/10.3390/nu11010044
work_keys_str_mv AT elderawiwafaaa theeffectsoforalmagnesiumsupplementationonglycemicresponseamongtype2diabetespatients
AT naserihaba theeffectsoforalmagnesiumsupplementationonglycemicresponseamongtype2diabetespatients
AT talebmahmmoudh theeffectsoforalmagnesiumsupplementationonglycemicresponseamongtype2diabetespatients
AT abutairaymans theeffectsoforalmagnesiumsupplementationonglycemicresponseamongtype2diabetespatients
AT elderawiwafaaa effectsoforalmagnesiumsupplementationonglycemicresponseamongtype2diabetespatients
AT naserihaba effectsoforalmagnesiumsupplementationonglycemicresponseamongtype2diabetespatients
AT talebmahmmoudh effectsoforalmagnesiumsupplementationonglycemicresponseamongtype2diabetespatients
AT abutairaymans effectsoforalmagnesiumsupplementationonglycemicresponseamongtype2diabetespatients